name

õ¿¬¹°¿¡¼­ ±â´É¼º¼ÒÀ縦 °³¹ßÇÏ¿© »óǰȭÇÏ´Â Àü¹®Áö½Ä°ú ±â¼ú·ÂÀ¸·Î õ¿¬¹ÙÀÌ¿À»ê¾÷ÀÇ ¹Ì·¡¸¦ °³Ã´ÇØ ³ª¾Æ°©´Ï´Ù
EstroG-100¢ç
ME.NO.PAUSE.
EstroG-100¢ç

EstroG-100¢ç (a blend of Cynanchi Wilfordii Radix and other complex extracts) is the first functional ingredient for women's menopause recognized by the Korean Ministry of Food and Drug Safety. It is a blend of Cynanchi Wilfordii Radix, Phlomis Umbrosa Turczaninow, and Angelica Gigas.
Through numerous clinical trials and research papers, its effectiveness in improving ten menopause symptoms has been confirmed. Notably, it does not affect estrogen levels (E2, FSH) and does not bind to estrogen receptors, ensuring it is safely consumed without risk of exacerbating women¡¯s health issues.
Additionally, EstroG-100¢ç has received global recognition, including NDI certification from the U.S. FDA, NPN licensing from Health Canada, and approval from the European Food Safety Authority as a novel food. It is cherished by many middle-aged and elderly women worldwide.

Exclusivity

Global Patent Overview
Phytoestrogenic Compositions for Preventing or Treating Symptoms Associated with Menopause
±Û·Î¹ú ƯÇã ȹµæ ÇöȲ¿¡ °ü·Ã µÈ Ç¥
Country registration number Country(s) registration number
South Korea 10-1141194 Europe (Germany, UK, France, Spain, Italy, Poland) 2370072
The United States 9,433,595
Canada 2745020 Mexico 328059
Russia 2491926 Malaysia MY-184493-A
China ZL200880132506.0 Indonesia ID.P.000050866
Australia 2008365666 Brazil PI0823391-8

Approval

±Û·Î¹ú ƯÇã ȹµæ ÇöȲ¿¡ °ü·Ã µÈ Ç¥
Country Permit name
The United States New Dietary Ingredient
Canada Natural Health Product
Europe Novel Food Ingredient
Japan Food and Drug Classification Search
Malaysia Food Supplement, Traditional Medicine
The Philippines Herbal Medicine
India Food for Special Dietary Use
Iran Natural Product
Egypt Herbal Medicine Product

Mechanism of Action

EstroG-100¢ç safely improves 10 menopausal symptoms without side effects related to estrogen activity
No adverse event at all subjects
No change in weight, BMI and liver enzymes
No change in serum E2 & FSH
No influence on estrogen-sensitive tissues
No binding affinities for ER¥á, ER¥â, and nonselective ER
No toxic effects shown in toxicity studies

5 Human clinical studies published

KMI(Kupperman menopause index, °»³â±âÁö¼ö) Improved by 62%
Improves 10 menopausal symptoms(Facial flushing and sweating, numbness in hands and
feet, insomnia, nervousness, depression, dizziness, fatigue, joint and
muscle pain, feeling cold, and vaginal dryness.)
¡Ø Phytother. Res. 2012, 26:510-6.
60 women aged 40-70 took it for 12 weeks
EstroG-100¢ç Satisfaction Improvement
Overall satisfaction reached 100%J Midlife Health. 2023, 14:285-290.

Numerous in vitro & in vivo studies

Facial flushing
  • Tail skin temperature (TST) ¡é
Osteoporosis
  • Femoral bone mineral density ¡è
Insomnia
  • Sleep induction time ¡é
  • Sleep continuity time ¡è
  • Recovery time ¡é
  • Melatonin in plasma & GABA in brain ¡è
Depression
  • Behavior evaluation ¡è
  • Serotonin & dopamine in brain¡è
  • Corticosterone in serum ¡è
Arthritis
  • Edema rate¡é
  • Cartilage maintenance factors (Col2¥á1, Aggrecan, Proteoglycan, SOX-9, Collagen I, Collage X) ¡è
  • Cartilage destruction factors (TIMP-1, MMP3, MMP7) ¡é
  • Degenerative osteoarthritis inducing factors (COX-2, MMP, NF-¥êB, TNF-¥á, IL-1¥â) ¡é
Fatigue
  • Glycogen content in muscle ¡è
  • LDH activity in muscle ¡é
  • Genetic expression of exercise fatigue recovery factors (PPAR-¥ä, UCP-3) ¡è
  • Antioxidant enzyme activity (SOD, CAT, GST) ¡è
  • Antioxidant compounds in liver (GSH) ¡è
  • Oxidative stress marker in liver (MDA) ¡é

Recommended dosage

175 ~ 514 mg/day